Engineering the Next Generation of Bispecific Antibodies

Strategies for engineering bi-, tri-, and multi-specific antibodies and emerging platform technologies will be premiered at Cambridge Healthtech Institute's Sixteenth Annual Engineering the Next Generation of Bispecific Antibodies track at PEGS Europe. This area is demonstrating tremendous progress and this forum will survey the current landscape and highlight emerging results in increasing targeting, efficacy, and specificity.

Scientific Advisory Board
Christian Klein, PhD, CXO in Residence & Drug Hunter, Curie.Bio
Harald Kolmar, PhD, Professor and Head, Institute for Organic Chemistry and Biochemistry, Technische Universität Darmstadt
Stefan Zielonka, PhD, Senior Director, Antibody Discovery and Protein Engineering, Merck Healthcare KGaA & Professor, Biomolecular Immunotherapy, Technische Universität Darmstadt

• Display of Biologics
• Engineering Antibodies
• Machine Learning Part 2

• Antibody-Based Therapies
• Emerging Targets
• Membrane Protein Targets

• Safety & Efficacy
• Advancing Multispecifics
• Engineering Bispecifics

• Immunoengineering
• Innovative CAR Therapy
• Next-Gen Immunotherapies

• Optimisation & Developability
• Analytical Characterisation
• Protein Stability & Formulation

• Leveraging Data Science
• Optimising Expression
• Developing Workflows

• Intro to Machine Learning
• Machine Learning Part 1
• Machine Learning Part 2

• Antibody-Based Therapies
• Engineering ADCs
• Next-Gen Immunotherapies

---

---

Related Event